News Headlines

  1. Cellipont Bioservices And CellVax Therapeutics Expand Partnership To Advance cGMP Manufacturing Of Personalized Immunotherapy FK-GI101 For GI Cancers 7/29/2025

    Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO) and CellVax Therapeutics Inc., a privately held clinical-stage biotechnology company focused on individualized cell-based immunotherapies, today announced a partnership expansion upon prior work on FK-PC101 - currently in a Phase II clinical trial for high-risk prostate cancer patients - and will include cGMP manufacturing, drug substance and drug product technology transfer, and GMP facility preparation in support of FK-GI101, an autologous cell-based immunotherapy targeting gastric, pancreatic, and colon cancer and the current FK-PC101 trial.

  2. Phlow Corp. And Antheia Partner To Bolster U.S. Pharmaceutical Supply Chains With Advanced Manufacturing Technologies 7/29/2025

    Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), and Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced an ongoing partnership to onshore production of essential medicines and establish more efficient, agile, and resilient pharmaceutical supply chains in the United States.

  3. Diorasis Therapeutics And Northway Biotech Announce Partnership For The Development And Manufacturing Of AAV Gene Therapy For Glaucoma 7/29/2025

    Diorasis Therapeutics ("DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic partnership with Northway Biotech ("NBT"), a contract development and manufacturing organization (CDMO), to establish a scalable cGMP production process for DTx’s lead AAV-based gene therapy candidate for open angle glaucoma.

  4. Ofichem Expands Drug Substance Capabilities With Acquisition Of Meribel Pharma Solutions' Uppsala Site In Sweden 7/29/2025

    Ofichem, a European CDMO specialising in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services, today announced the acquisition of Meribel Pharma Solutions’ site in Uppsala, Sweden.

  5. ViroCell Biologics And AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration To Accelerate Development Of Novel Allogeneic CAR-T Therapies For Blood Cancers 7/29/2025

    ViroCell Biologics (“ViroCell”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. (“AvenCell”), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies.

  6. Introducing Arcinova, A Quotient Sciences Company 7/28/2025

    Arcinova offers solutions tailored for early development, from candidate selection through to proof of concept. This means faster, more efficient development pathways, deeper scientific expertise and expanded access to specialized services to help you bring innovative therapies to patients sooner.

  7. Simtra BioPharma Solutions Announces Strategic Purchase To Expand U.S. Manufacturing Capacity For Injectable Medicines 7/25/2025

    Simtra BioPharma Solutions, a leading global contract development and manufacturing (CDMO) specializing in injectable medicines, announced today the purchase from Cook Group of a 65-acre property (301 N. Curry Pike) with more than 300,000 square feet of available space for expansion under-roof near its existing manufacturing facility in Bloomington, Indiana.

  8. Fagron Sterile Services US Awarded National Outsourced Compounded Preparations Agreement With Premier, Inc. 7/24/2025

    Fagron Sterile Services US (FSS), a leading DEA & FDA registered 503B pharmaceutical outsourcing company, announced today that it has been awarded a national group purchasing agreement for compounded sterile services with Premier, Inc.

  9. Colorcon Celebrates Grand Opening of New Manufacturing Facility in Malaysia 7/24/2025

    Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere packaging for the pharmaceutical and nutraceutical industries, today announced the grand opening of a new, state-of-the-art film coating manufacturing facility in Johor Malaysia.

  10. Pfizer Completes Licensing Agreement With 3SBio 7/24/2025

    Pfizer Inc. announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio’s proprietary CLF2 platform.